Audio Journal of Oncology Podcast Ibrutinib: New Frontline Standard for Chronic Lymphocytic Leukemia? Play Episode Pause Episode Mute/Unmute Episode...
Audio Journal of Oncology Podcast Head and Neck Cancer Therapy De-Escalation: A “Salutary Lesson” Play Episode Pause Episode Mute/Unmute Episode...
Audio Journal of Oncology Podcast Which New Combination for Metastatic Renal Cell Cancer? Play Episode Pause Episode Mute/Unmute Episode Rewind 10...
Audio Journal of Oncology Podcast Two Drug Combination Doubled Kidney Cancer Progression Free Survival Play Episode Pause Episode Mute/Unmute Episode...
Audio Journal of Oncology Podcast ALK—Targeted Lung Cancer Drugs Benefited Real World Patients Play Episode Pause Episode Mute/Unmute Episode Rewind...
Audio Journal of Oncology Podcast First Line PARP Inhibition For Ovarian Cancer Assessed Play Episode Pause Episode Mute/Unmute Episode Rewind 10...
Audio Journal of Oncology Podcast BRCA1/2 Ovarian Cancer—Three Years Disease Free with First-Line Olaparib Play Episode Pause Episode Mute/Unmute...
Audio Journal of Oncology Podcast PD-L1 Immunotherapy Delayed Triple Negative Breast Cancer Progression Play Episode Pause Episode Mute/Unmute...
Audio Journal of Oncology Podcast Genomically Targeted Therapy Delays Advanced Breast Cancer Progression Play Episode Pause Episode Mute/Unmute...
Audio Journal of Oncology Podcast Palbociclib Combination Prolongs Life After Breast Cancer Hormone Therapy Play Episode Pause Episode Mute/Unmute...
Audio Journal of Oncology Podcast Long Overall Survival in Ceritinib-Treated ALK-Positive Lung Cancer Play Episode Pause Episode Mute/Unmute Episode...
Reporter: Sarah Maxwell BARCELONA—Pembrolizumab did not significantly improve overall survival (OS) or progression free survival (PFS) compared with...